Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mega GenomicsHKSE:06667 -0.28%71 Days Payable is 136.79 as of Dec. 2025, which is 28% below its 10-year median of 190.39. GuruFocus rates HKSE:06667 with a GF Score™ of 71/100 and a GF Value™ of HK$16.92 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Mega Genomics ranks better than 76.44% on this metric.
The historical rank and industry rank for Mega Genomics's Days Payable or its related term are showing as below:
HKSE:06667'
s Days Payable Range Over the Past 10 Years
Min: 96.87 Med: 190.39 Max: 268.15
Current: 166.77
During the past 7 years, Mega Genomics's highest Days Payable was 268.15. The lowest was 96.87. And the median was 190.39.
HKSE:06667's Days Payable is ranked better than 76.44% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.6
vs HKSE:06667: 166.77
Mega Genomics's Days Payable
declined
from Dec. 2024 (938.26) to Dec. 2025 (136.79).
It may suggest that Mega Genomicsaccelerated paying its suppliers.
The historical data trend for Mega Genomics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06667 vs TMO, DHR, NTRA: Days Payable Comparison
For the Diagnostics & Research subindustry, Mega Genomics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Genomics Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's Days Payable distribution charts can be found below:
* The bar in red indicates where Mega Genomics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mega Genomics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mega Genomics (HKSE:06667) has a Days Payable of 136.79 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mega Genomics and its competitors. This is 28% below median its historical median of 190.39. Over the past decade, Mega Genomics' Days Payable has ranged from 96.87 to 268.15. According to the industry distribution chart, Mega Genomics ranks #45 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 23.6%.
Is Mega Genomics' Days Payable too high?
Mega Genomics' current Days Payable of 136.79 is 28% below median its 10-year median of 190.39. Over the past 10 years, this metric has ranged from a low of 96.87 to a high of 268.15. The Medical Diagnostics & Research industry median Days Payable is 67.60. Mega Genomics' value of 136.79 is 102.4% above this industry median. Based on the distribution chart, Mega Genomics ranks #45 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Mega Genomics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mega Genomics' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Mega Genomics ranks #45 out of 191 companies for Days Payable. This places Mega Genomics in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.60. Mega Genomics' value of 136.79 is 102.4% above this benchmark. Historically, Mega Genomics' own Days Payable has ranged from 96.87 to 268.15 over the past decade. While the company's 10-year median is 190.39 vs. the industry median of 67.60, Mega Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.60, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mega Genomics's current Days Payable of 136.79 is 102.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mega Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mega Genomics's current Days Payable is 136.79, which is 28% below median its own 10-year median of 190.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mega Genomics stock overvalued right now?
Based on GuruFocus' analysis, Mega Genomics (HKSE:06667) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.92, compared to a current price of HK$7.08 — trading 58.2% below its estimated fair value. The current Days Payable is 136.79, which is 28% below median its 10-year median of 190.39 and 102.4% above the Medical Diagnostics & Research industry median of 67.60. Mega Genomics' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mega Genomics (HKSE:06667), the current Days Payable is 136.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mega Genomics (HKSE:06667) Overvalued in 2026?
Based on GuruFocus' analysis, Mega Genomics stock appears to be undervalued.
The current stock price of HK$7.08 is trading 58.2% below its estimated GF Value™ of HK$16.92.
GuruFocus considers Mega Genomics to be Possible Value Trap.
Key valuation signals for HKSE:06667:
Days Payable: 136.79 (28% below median its 10-year median of 190.39)
GF Value™: HK$16.92 vs. price of HK$7.08 (58.2% below fair value)
Industry Position: 102.4% above the Medical Diagnostics & Research median (#45 of 191)
No single metric tells the full story. See the HKSE:06667 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services, ancillary services, and related products in the PRC. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers' growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
71GF Score
Get the complete analysis for HKSE:06667
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06667 has been successfully added to your 
